
In today’s briefing:
- Raffles Medical (RFMD SP): 2H24 Result, China Recovery, Buyback, and Dividend Raise Expectation
- SpringWorks Therapeutics in Advanced Acquisition Talks with Merck KGaA Amid FDA Approval and Growth Potential
- Mesoblast (MSB AU): ‘Comparable’ Pricing for Ryoncil; US Commercialization Is Progressing
- Actinver Research – Genomma Lab 4Q24: Healthy finish of the year (Quick View)
- Visen Pharmaceuticals (维升药业) IPO: PHIP Updates Don’t Look Positive
- EVAX: Extended Trial is Excellent News
- MGRM: Monogram announces regulatory update on its 510(k) premarket filing submission to the FDA. The company also provided updates on the Shalby Limited clinical trial in India.
- BBLG: Funding Looks Good as Trials Continue

Raffles Medical (RFMD SP): 2H24 Result, China Recovery, Buyback, and Dividend Raise Expectation
- Raffles Medical Group (RFMD SP) reported mixed 2024 result. However, 2H24 revenue increased 15% YoY, operating profit rose 5% YoY, and adjusted PATMI jumped 38% YoY.
- China operation is recovering, with revenue growing 10% YoY to S$65M in 2024. Three general hospitals in China have demonstrated strong potential for growth and have a positive outlook ahead.
- Raffles has revised its dividend policy to pay out at least 50%. The company intends to buy back up to 100M ordinary shares over the next two years.
SpringWorks Therapeutics in Advanced Acquisition Talks with Merck KGaA Amid FDA Approval and Growth Potential
- SpringWorks Therapeutics is in advanced acquisition talks with Merck KGaA, following FDA approval for its drug Gomekli.
- Merck’s acquisition strategy focuses on low-risk, value-creating oncology deals, aligning with SpringWorks’ FDA-approved treatments.
- Estimated peak sales for SpringWorks’ drugs range from $600m to $1bn, suggesting a potential $85/share valuation.
Mesoblast (MSB AU): ‘Comparable’ Pricing for Ryoncil; US Commercialization Is Progressing
- Mesoblast Ltd (MSB AU) has announced pricing for Ryoncil in the U.S. in tandem with the economic value of treatment with product availability planned for the current quarter.
- Wholesale acquisition cost of Ryoncil has been set at $194K per infusion. Ryoncil infusion is given twice per week for 4 weeks. This brings the full treatment cost to $1.55M.
- The pricing is strategically determined against the cost of treating a child who dies of SR-aGvHD of $2.5M and calculated total benefits of patient outcomes using Ryoncil of $3.2–4.1M.
Actinver Research – Genomma Lab 4Q24: Healthy finish of the year (Quick View)
- Revenues of P$4.7bn grew 32.4% YoY, supported by healthy growth across all regions.
- Sales in Mexico were in line with our estimates, while in LatAm and the U.S. they were slightly lower than expected, with the former still posting a solid growth vs an easy comp base amid improving conditions in the region.
- In the U.S., a weaker flu season partially impacted sales.
Visen Pharmaceuticals (维升药业) IPO: PHIP Updates Don’t Look Positive
- Visen Pharmaceuticals is looking at raising up to USD 300m to list in Hong Kong.
- The company has passed the hearing for the listing and filed a new version of the prospectus.
- We look at the difference between previous filing and current filing. Most of the changes are not critical but we think overall it doesn’t look good.
EVAX: Extended Trial is Excellent News
- EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.
- The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.
- The company announced that a key Phase 2 trial was being extended due to the positive results seen to this point, which is a very positive sign for the treatment potential of EVX-01.
MGRM: Monogram announces regulatory update on its 510(k) premarket filing submission to the FDA. The company also provided updates on the Shalby Limited clinical trial in India.
- Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging.
- The company delivered its first surgical robot in November 2023 and submitted its 510(k) on July 19th and the application passed the Administrative Review.
- The first live in patient surgery OUS is expected in early 2025.
BBLG: Funding Looks Good as Trials Continue
- Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1.
- The company released its full year 2024 financial results that showed good cash, low debt and good cost controls.
- The company continues with human trials, and we are looking forward to the initial results.